vs

Side-by-side financial comparison of Canaan Inc. (CAN) and ImmunityBio, Inc. (IBRX). Click either name above to swap in a different company.

ImmunityBio, Inc. is the larger business by last-quarter revenue ($38.3M vs $20.8M, roughly 1.8× Canaan Inc.). Canaan Inc. runs the higher net margin — -18.4% vs -161.8%, a 143.4% gap on every dollar of revenue.

Canaan Inc., doing business as Canaan Creative and known simply as Canaan, is a Singapore-based computer hardware manufacturer. Established in 2013 by N.G. Zhang, Canaan specializes in Blockchain servers and ASIC microprocessors for use in bitcoin mining.

ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing next-generation immunotherapies and vaccine candidates targeting multiple cancer types and infectious diseases. It operates mainly in the U.S. market, with core R&D segments including cell therapy, antibody therapeutics, and targeted vaccine platforms designed to enhance patient treatment outcomes.

CAN vs IBRX — Head-to-Head

Bigger by revenue
IBRX
IBRX
1.8× larger
IBRX
$38.3M
$20.8M
CAN
Higher net margin
CAN
CAN
143.4% more per $
CAN
-18.4%
-161.8%
IBRX

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
CAN
CAN
IBRX
IBRX
Revenue
$20.8M
$38.3M
Net Profit
$-3.8M
$-61.9M
Gross Margin
99.9%
99.0%
Operating Margin
-15.9%
-169.0%
Net Margin
-18.4%
-161.8%
Revenue YoY
407.0%
Net Profit YoY
-4.7%
EPS (diluted)
$-0.05
$-0.06

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CAN
CAN
IBRX
IBRX
Q4 25
$20.8M
$38.3M
Q3 25
$13.8M
$32.1M
Q2 25
$11.4M
$26.4M
Q1 25
$16.5M
Q4 24
$7.6M
Q3 24
$10.2M
$6.1M
Q2 24
$4.8M
Net Profit
CAN
CAN
IBRX
IBRX
Q4 25
$-3.8M
$-61.9M
Q3 25
$-1.5M
$-67.3M
Q2 25
$-11.9M
$-92.6M
Q1 25
$-129.6M
Q4 24
$-59.2M
Q3 24
$-10.4M
$-85.7M
Q2 24
$-5.4M
Gross Margin
CAN
CAN
IBRX
IBRX
Q4 25
99.9%
99.0%
Q3 25
99.9%
99.4%
Q2 25
99.9%
99.5%
Q1 25
99.6%
Q4 24
Q3 24
99.9%
Q2 24
99.8%
Operating Margin
CAN
CAN
IBRX
IBRX
Q4 25
-15.9%
-169.0%
Q3 25
-27.0%
-173.5%
Q2 25
-45.5%
-269.8%
Q1 25
-390.1%
Q4 24
-919.0%
Q3 24
-77.2%
-1314.3%
Q2 24
-193.9%
Net Margin
CAN
CAN
IBRX
IBRX
Q4 25
-18.4%
-161.8%
Q3 25
-11.0%
-209.8%
Q2 25
-104.4%
-350.3%
Q1 25
-784.9%
Q4 24
-783.4%
Q3 24
-102.7%
-1404.0%
Q2 24
-112.3%
EPS (diluted)
CAN
CAN
IBRX
IBRX
Q4 25
$-0.05
$-0.06
Q3 25
$-0.02
$-0.07
Q2 25
$-0.25
$-0.10
Q1 25
$-0.15
Q4 24
$-0.08
Q3 24
$-0.14
Q2 24

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CAN
CAN
IBRX
IBRX
Cash + ST InvestmentsLiquidity on hand
$242.8M
Total DebtLower is stronger
$6.2M
Stockholders' EquityBook value
$52.4M
$-500.5M
Total Assets
$92.5M
$501.9M
Debt / EquityLower = less leverage
0.12×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CAN
CAN
IBRX
IBRX
Q4 25
$242.8M
Q3 25
$257.8M
Q2 25
$153.7M
Q1 25
$61.6M
Q4 24
$149.8M
Q3 24
$130.4M
Q2 24
Total Debt
CAN
CAN
IBRX
IBRX
Q4 25
$6.2M
Q3 25
$6.2M
Q2 25
$6.2M
Q1 25
Q4 24
Q3 24
Q2 24
Stockholders' Equity
CAN
CAN
IBRX
IBRX
Q4 25
$52.4M
$-500.5M
Q3 25
$44.7M
$-524.3M
Q2 25
$33.8M
$-570.7M
Q1 25
$-591.4M
Q4 24
$-489.1M
Q3 24
$43.6M
$-745.1M
Q2 24
$56.8M
Total Assets
CAN
CAN
IBRX
IBRX
Q4 25
$92.5M
$501.9M
Q3 25
$81.7M
$519.0M
Q2 25
$78.0M
$402.1M
Q1 25
$303.8M
Q4 24
$382.9M
Q3 24
$69.3M
$364.6M
Q2 24
$73.7M
Debt / Equity
CAN
CAN
IBRX
IBRX
Q4 25
0.12×
Q3 25
0.14×
Q2 25
0.18×
Q1 25
Q4 24
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CAN
CAN
IBRX
IBRX
Operating Cash FlowLast quarter
$-70.4M
Free Cash FlowOCF − Capex
$-71.3M
FCF MarginFCF / Revenue
-186.2%
Capex IntensityCapex / Revenue
2.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-308.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CAN
CAN
IBRX
IBRX
Q4 25
$-70.4M
Q3 25
$-68.9M
Q2 25
$-79.7M
Q1 25
$-85.9M
Q4 24
$-85.1M
Q3 24
$-98.8M
Q2 24
Free Cash Flow
CAN
CAN
IBRX
IBRX
Q4 25
$-71.3M
Q3 25
$-69.6M
Q2 25
$-80.8M
Q1 25
$-87.0M
Q4 24
$-87.3M
Q3 24
$-101.6M
Q2 24
FCF Margin
CAN
CAN
IBRX
IBRX
Q4 25
-186.2%
Q3 25
-217.2%
Q2 25
-305.9%
Q1 25
-526.9%
Q4 24
-1155.4%
Q3 24
-1663.2%
Q2 24
Capex Intensity
CAN
CAN
IBRX
IBRX
Q4 25
2.4%
Q3 25
2.3%
Q2 25
4.1%
Q1 25
6.8%
Q4 24
28.0%
Q3 24
45.7%
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons